Active Interleukin 35 (IL35) Homo sapiens (Human) Active protein

  • UOM
    1. 10µg
    2. 50µg
    3. 200µg
    4. 1mg
    5. 5mg
  • FOB US$ 200.00 US$ 500.00 US$ 1,000.00 US$ 3,000.00 US$ 7,500.00
  • Quantity
    In stock
Add to Cart Distributors Free trial
  • Buffer Formulation20mM Tris, 150mM NaCl, pH8.0, containing 1mM EDTA, 1mM DTT, 0.01% SKL, 5% Trehalose and Proclin300.
  • Traits Freeze-dried powder, Purity > 97%
  • Isoelectric Point8.7
Share your citation Upload your experimental result Review Leave a message

Share a new citation as an author

Upload your experimental result


Please attach serial No. on instruction manual

Contact us

Please fill in the blank.

E-mail address*
Verification code* CheckCode
  • Active Interleukin 35 (IL35) Packages (Simulation)
  • Active Interleukin 35 (IL35) Packages (Simulation)
  • Active Interleukin 35 (IL35) Gene sequencing
  • APC008Hu01.jpg Figure. SDS-PAGE; Sample: Active recombinant IL35, Human.
  • Active Interleukin 35 (IL35) Figure. Western Blot; Sample: Recombinant IL35, Human.
  • Certificate ISO9001: 2008, ISO13485: 2003 Registered

Activity test

IL35 (Interleukin 35) is an IL-12 family cytokine, which is a dimeric protein composed of IL-12α and IL-27β chains. IL35 is thought to mediate the immune inhibitory function of regulatory T cells and has been proven to promotes pancreas cancer growth through enhancement of proliferation and inhibition of apoptosis. Thus, proliferation assay of IL35 was conducted using PANC-1 cells. Briefly,
PANC-1 cells were seeded into triplicate wells of 96-well plates at a density of 2,000 cells/well and allowed to attach overnight, then the medium was replaced with serum-free standard DMEM prior to the addition of various concentrations of recombinant human IL35. After incubated for 48h, cells were observed by inverted microscope and cell proliferation was measured by Cell Counting Kit-8 (CCK-8). Briefly, 10µL of CCK-8 solution was added to each well of the plate, then the absorbance at 450nm was measured using a microplate reader after incubating the plate for 1-4 hours at 37°C. Proliferation of PANC-1 cells after incubation with IIL35 for 48h observed by inverted microscope was shown in Figure 1. Cell viability was assessed by CCK-8 (Cell Counting Kit-8 ) assay after incubation with human recombinant IL35 for 48h. The result was shown in Figure 2. It was obvious that IL35 significantly increased cell viability of PANC-1 cells.


Reconstitute in 20mM Tris, 150mM NaCl (pH8.0) to a concentration of 0.1-1.0 mg/mL. Do not vortex.


Avoid repeated freeze/thaw cycles. Store at 2-8°C for one month. Aliquot and store at -80°C for 12 months.


The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.


  • Aberrant expression of Treg-associated cytokine IL-35 along with IL-10 and TGF-β in acute myeloid leukemia.PubMed: 22783403
  • Plasma IL-17, IL-35, interferon-γ, SOCS3 and TGF-β levels in pregnant women with preeclampsia, and their relation with severity of diseasePubmed: 24175856
  • What is the impact of Th1/Th2 ratio, SOCS3, IL17, and IL35 levels in unexplained infertility?Pubmed: 24368037
  • The imbalanced profile and clinical significance of T helper associated cytokines in bone marrow microenvironment of the patients with acute myeloid leukemiaScienceDirect: S0198885913005776
  • Gene Expression of Subunits of the IL-12 Family Cytokines in moDCs Derived In Vitro from the Cord Blood of Children of Healthy and Allergic MothersPubmed:24785110
  • Function of interleukin?17 and ?35 in the blood of patients with hepatitis B?related liver cirrhosisPubmed:25323532
  • The regular distribution and expression pattern of immunosuppressive cytokine IL-35 in mouse uterus during early pregnancyPubmed:25611266
  • Wogonin Inhibits Tumor-derived Regulatory Molecules by Suppressing STAT3 Signaling to Promote Tumor ImmunityPubMed: 25962106
  • Interleukin 35 Synovial Fluid Levels Are Associated with Disease Activity of Rheumatoid ArthritisPubMed: 26204444
  • Interleukin-35 is upregulated in systemic sclerosis and its serum levels are associated with early diseasePubMed: 26231346
  • Anti-inflammatory effects of interleukin-35 in acquired aplastic anemiaPubMed: 26282938
  • Interleukin-35 Inhibits Endothelial Cell Activation by Suppressing MAPK-AP-1 PathwayPubMed: 26085094
  • Interleukin 35 may contribute to the loss of immunological self‐tolerance in patients with primary immune thrombocytopeniaPubMed: 25640666
  • New insights into immune mechanisms underlying response to Rituximab in patients with membranous nephropathy: A prospective study and a review of the literaturePubmed:26876383
  • Increased plasma concentrations of interleukin 35 in patients with coronary artery diseaseJournal:-19
  • The clinical utility of serum IL-35 in patients with polymyositis and dermatomyositispubmed:27502600
  • Enhanced LPS-induced activation of IL-27 signalling in sarcoidosispubmed:27492538
  • Effects of an intravitreal injection of interleukin-35-expressing plasmid on pro-inflammatory andanti-inflammatory cytokines.pubmed:27460435
  • IL-35在牙周炎及口腔扁平苔藓中的表达及相关性分析QK:98604X

Recommend products